In what clinical settings are the MASAI trial results applicable?

Nature Reviews Clinical Oncology has published a commentary analyzing the clinical significance of the MASAI (Mammography Screening with Artificial Intelligence) trial, which is believed to be the first randomized controlled trial of AI-supported mammography interpretation to evaluate interval cancer rates as an endpoint. The Swedish trial demonstrated that using artificial intelligence to triage mammograms for single-reading versus traditional double-reading does not lead to an increase in interval cancers — tumors detected between scheduled screening rounds. This finding is critical because interval cancers are a key safety metric in breast screening programs, and any AI-driven workflow change must prove it does not compromise cancer detection. The commentary discusses the broader applicability of the MASAI results across different clinical and population settings, addressing whether the benefits observed in Sweden can be generalized to other screening programs worldwide.